Table 1. Characteristics of Study Population.
| Characteristics | Developmental Cohort (n = 1480) | Test Cohort (n = 738) | P |
|---|---|---|---|
| Age (years) | 30.9 ± 9.1 (18–62) | 31.3 ± 8.9 (18–58) | 0.40 |
| Sex (female)* | 534 (36.1) | 245 (33.2) | 0.18 |
| Pathologic steatosis grade* | 0.95 | ||
| None (≤ 5%) | 860 (58.1) | 428 (58.0) | |
| Mild (> 5%) | 517 (34.9) | 256 (34.7) | |
| Moderate/severe (≥ 33%) | 103 (7.0) | 54 (7.3) | |
| BMI (kg/m2) | 23.3 ± 3.2 (15.4–41.3) | 23.4 ± 3.0 (15.4–34.9) | 0.69 |
| Laboratory findings | |||
| AST (IU/mL) | 21.3 ± 11.7 (10–365) | 21.4 ± 8.2 (10–129) | 0.77 |
| ALT (IU/mL) | 20.3 ± 13.6 (1–181) | 20.9 ± 13.1 (6–121) | 0.29 |
| Bilirubin (ng/mL) | 0.98 ± 0.37 (0.2–3.5) | 1.00 ± 0.39 (0.3–4.1) | 0.23 |
| ALP (IU/mL) | 62.87 ± 18.22 (20–186) | 62.70 ± 18.30 (10–182) | 0.84 |
| Triglyceride (mg/dL) | 103.81 ± 77.22 (17–935) | 108.02 ± 88.85 (21–1304) | 0.25 |
| Cholesterol (mg/dL) | 173.74 ± 32.83 (68–320) | 174.77 ± 32.51 (98–302) | 0.48 |
| HDL-cholesterol (mg/dL) | 50.70 ± 13.27 (20–106) | 50.40 ± 12.95 (19–94) | 0.61 |
| Glucose (mg/dL) | 94.54 ± 15.02 (58–370) | 95.19 ± 17.05 (63–374) | 0.36 |
| Albumin (g/dL) | 4.37 ± 0.29 (3.2–5.2) | 4.37 ± 0.27 (3.5–5.2) | 0.97 |
| Hepatic steatosis index | 31.45 ± 4.91 (20–54) | 31.62 ± 4.50 (21–47) | 0.43 |
| Fatty liver disease index | 27.28 ± 4.19 (24–30) | 27.45 ± 4.03 (25–30) | 0.25 |
Unless otherwise indicated, data are mean ± standard deviation; data in parentheses are range. *Number (percentages) of patients.
ALP = alkaline phosphatase, ALT = alanine aminotransferase, AST = aspartate transaminase, BMI = body mass index, HDL = high-density lipoprotein